Comparative Pharmacology
Head-to-head clinical analysis: CUBICIN RF versus CYCLACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUBICIN RF versus CYCLACILLIN.
CUBICIN RF vs CYCLACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
250-500 mg orally every 6 hours.
None Documented
None Documented
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment.
Clinical Note
moderateCyclacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."
Clinical Note
moderateCyclacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."
Clinical Note
moderateCyclacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."
Clinical Note
moderate0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%).
Primarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Category C
Category C
Antibiotic
Antibiotic
Cyclacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin."